
Conference Coverage
Latest Content

Shorts










Videos
Continuing Medical Education
All News

Beth Sandy, MSN, CRNP, FAPO, reviewed ADCs, immunotherapy, and targeted therapy in NSCLC with a focus on what nurses should monitor.

Neladalkib produced response rates of 49% after alectinib and 32% after multiple ALK TKIs plus chemotherapy in the ALKOVE-1 trial.

JoAnne Page, RN, a breast cancer survivor, shares what oncology nurses can do for care partners of patients with bladder cancer.

Giredestrant (Wilserdly) plus everolimus nearly doubled median PFS vs standard endocrine therapy plus everolimus in ESR1-mutated disease in evERA.

Alembic's generic binimetinib, in 15 mg and 45 mg tablets, is therapeutically equivalent to Mektovi for BRAF-mutant melanoma and NSCLC.

The field of oncology continues to evolve, driven by novel drug approvals, innovative delivery technologies, and emerging care strategies in cancer survivorship.

Pertuzumab-qcay is the second FDA-approved biosimilar to Perjeta, but a settlement with Genentech delays its US launch until Q3 2028.

The FDA declined to approve ivonescimab plus chemotherapy after EGFR TKI therapy, citing no statistically significant OS gain in HARMONi.

Cancer care teams are supporting more patients than ever, and oncology teams are navigating the clinical and operational realities that come with that growth.

A 5-decade SEER analysis found 5-year survival in young patients rose from 60% to 90%, yet non-Hispanic Black patients fared worst across cancers.

Nurses earn public trust through quiet acts of compassion, reassurance, and presence — a vital lifeline especially in oncology care.

Modeling projects anthracycline recipients may lose a median 9.4 life-years to age acceleration, a finding with survivorship care implications.

Oncology NPs and PAs are key to closing workforce gaps. Here’s how generalist, specialist, and hybrid APP models improve access and outcomes.

Perioperative durvalumab with enfortumab vedotin given only before cystectomy cut the risk of an EFS event by 49% in the phase 3 VOLGA trial.

With 10 years of oncology nursing experience, Lee Grabb highlights how nurse navigation, human connection, and compassion transform holistic cancer care.





































































